This article is more than 5 years old. Information may no longer be current.
FDA OKs rapid-acting insulin to be used in insulin pumps, other top stories in Endocrinology
News that the FDA approved the use of insulin aspart injection 100 U/mL in insulin infusion pumps to improve glycemic response in adults with diabetes was one of the top stories in endocrinology last week.
Study results that showed women who breastfeed for at least a year were less likely to develop type 2 diabetes and hypertension in the following 10 years was another top story.
FDA approves rapid-acting insulin for pump use
The FDA expanded the indication for insulin aspart injection 100 U/mL to include use in insulin infusion pumps for the improvement of glycemic response in adults with type 1 and type 2 diabetes, according to a press release from Novo Nordisk. Read more.
Breastfeeding can ‘reset’ adverse metabolic profile after pregnancy
Women who breastfeed for at least 12 months are 30% less likely to develop type 2 diabetes and 13% less likely to develop hypertension during 10 years of follow-up when compared with women who never breastfed, according to a meta-analysis of more than 200,000 women published in JAMA Network Open. Read more.
Weight-loss medications continue to be prescribed at ‘low rates’
Among eligible adults with overweight or obesity, only 1.3% were prescribed weight-loss medications, according to findings published in Obesity. Read more.
Diabetes increases risks for certain infections
Adults with diabetes have increased risks for infections, such as influenza, cellulitis and sepsis, compared with adults without diabetes, according to findings published in Diabetes Care. Read more.
Canagliflozin ‘not your mother’s diabetes lowering drug’ due to kidney benefits
CHICAGO — The protective benefits for the kidney and cardiovascular system from SGLT2 inhibitor therapy may be more critical than the more traditional diabetes treatment effects of this medication class, according to a speaker at the Cardiometabolic Health Congress. Read more.